Forest Labs Reps Marketed Daliresp Off-Label, FDA Says
The U.S. Food and Drug Administration has accused Forest Laboratories Inc. of allowing two sales representatives to push its chronic obstructive pulmonary disease drug Daliresp for off-label use, despite a promotional...To view the full article, register now.
Already a subscriber? Click here to view full article